As pricing pressures intensify, timelines compress, and policy changes take hold, manufacturers are rethinking how they gather and apply strategic insight. We sat down with Julian Casciano, President and CEO of eMAX Health Systems, to get his perspective on what high-performing teams are doing differently and how platforms like MAVA are helping them keep pace.
Q: What’s the biggest shift you’re seeing in market access today?Executive Insight: What Pharma Leaders Need to Know
Julian: The pace. Everything is moving faster, including launch timelines, pricing pressures, and policy changes. Teams used to have the luxury of long planning cycles. Now, if you’re not gathering insight and adapting strategy in real time, you’re already behind.
Q: What are high-performing teams doing differently?
Julian: They’re no longer relying on static research or one-off advisory boards. They’re building flexible, iterative feedback loops into their entire commercialization process. They understand that assumptions need to be pressure-tested continuously.
Q: What kind of insight matters most right now?
Julian: Payer and provider input that’s current, directional, and fast. Teams need answers as well as the ability to ask the next question the moment a new variable emerges. That agility is what makes the difference between launch readiness and launch risk.
Q: Where does MAVA fit in?
Julian: We built MAVA to deliver that kind of insight infrastructure. Yes, it’s about asking questions, but more importantly, about having access to the right decision-makers, iterating in real time, and modeling different strategies as the market evolves. Tools like Elasticity™ and Contracting ROI make it possible to test price, value, and rebate scenarios with real data from the people who influence access.
Q: Any final advice for teams planning a launch?
Julian: Build your insight engine early. Make it dynamic. And never assume your first answer is your final one.